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Available online 26 May 2016Parathyroid hormone (PTH) plays critical, but distinct, roles in bone remodeling, including bone formation (an-
abolic response) and resorption (catabolic response). Although its signaling and function have been extensively
investigated, it just began to be understood how distinct functions are induced by PTH activating a common re-
ceptor, the PTH type 1 receptor (PTH1R), and how PTH1R signaling is terminated. Here, we provide evidence for
vacuolar protein sorting 35 (VPS35), a major component of retromer, in regulating PTH1R trafﬁcking, turning off
PTH signaling, and promoting its catabolic function. VPS35 is expressed in osteoblast (OB)-lineage cells. VPS35-
deﬁciency in OBs impaired PTH(1–34)-promoted PTH1R translocation to the trans-Golgi network, enhanced
PTH(1–34)-driven signaling, and reduced PTH(1–34)'s catabolic response in culture and inmice. Furthermechanical
studies revealed that VPS35 interactswith not only PTH1R, but also protein phosphatase 1 regulatory subunit 14C
(PPP1R14C), an inhibitory subunit of PP1 phosphatase. PPP1R14C also interacts with PTH1R, which is necessary
for the increased endosomal PTH1R signaling and decreased PTH(1–34)'s catabolic response in VPS35-deﬁcient
OB-lineage cells. Taken together, these results suggest that VPS35 deregulates PTH1R-signaling likely by its inter-
action with PTH1R and PPP1R14C. This event is critical for the control of PTH(1–34)-signaling dynamics, which
may underlie PTH-induced catabolic response and adequate bone remodeling.
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VPS35 is a critical component of the cargo-recognition sub-complex of
retromer that contains VPS26, VPS29, and VPS35. Clinically, VPS35/
retromerdysfunctionisarisk factor forpathogenesisofneurodegenerative
disorders, includingAlzheimer'sdisease(AD)andParkinson'sdisease(PD)
(Dhungeletal., 2015;Muhammadetal., 2008;Small etal., 2005;Small and
Petsko, 2015; Tang et al., 2015a; Tang et al., 2015b; Vilarino-Guell et al.,
2011;Wen et al., 2011; Zimprich et al., 2011). Intriguingly, in addition to
neurodegenerative pathology, AD patients frequently have lower bone-
mass and higher hip fracture rate, compared with the same age normal
population(Luckhaus et al., 2009; Melton et al., 1994; Sato et al., 1998;
Sato et al., 2004; Tan et al., 2005; Tysiewicz-Dudek et al., 2008); and
somePDpatientshavePagetdiseaseof thebone, achronicdisorder caused
by the excessive bone resorption and formation (Helfrich and Hocking,
2008; Reid, 2012). In addition to VPS35, several newly identiﬁed AD risk
genes/loci (e.g., TREM2, andPYK2) encodeproteins critical for osteoclastice & Regenerative Medicine and
gusta, GA 30912., United States.
ss article under the CC BY-NC-ND licactivationandbonehomeostasis(Duongetal.,1998;Guerreiroetal., 2013;
Paloneva et al., 2003; Pfaff and Jurdic, 2001; Singaraja, 2013; Small et al.,
2005;Wang et al., 2003). Thus, increasing evidence from clinical and ge-
netic studies supports adegreeof co-morbidityof thesedisorders.Howev-
er, very few studies are available to address their relationship.
Cell biologically, the retromer complex is essential for retrieval of
transmembrane proteins or receptors from endosome-to-Golgi appara-
tus (Bonifacino and Hurley, 2008; McGough and Cullen, 2011; Seaman
et al., 2013; Seaman et al., 1997). A growing list of retromer cargos has
been identiﬁed, such as VPS10/sortilin/SorLA family proteins(Seaman,
2005), cation-independent M6P receptor (CI-M6PR) (Seaman, 2004),
mammalian iron transporter DMT1(Tabuchi et al., 2010), amyloid pre-
cursor protein (APP) (Vieira et al., 2010), APP processing β1 secretase
(BACE1) (Wen et al., 2011), Caenorhabditis elegans phagocytosis recep-
tor Ced1(Chen et al., 2010), receptor activator of nuclear factor kappa-B
(RANK) (Xia et al., 2013b), and seven transmembrane receptors such as
Wntless (Belenkaya et al., 2008; Pan et al., 2008; Yang et al., 2008), β2-
adrenergic receptor (Choy et al., 2014; Temkin et al., 2011), and PTH1R
(type 1 receptor for parathyroid hormone) (Feinstein et al., 2011). Thus,
VPS35/retromer is likely to be involved in various cellular functions or
processes via its regulation of different cargos.ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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eling or bone homeostasis. First, VPS35 is highly expressed in both
OB- and OC-lineage cells (Xia et al., 2013b). Second, VPS35/retromer's
cargos, such as PTH1R, Wntless, and RANK, are critical for bone remod-
eling or bone homeostasis (Cheloha et al., 2015; Coudreuse et al., 2006;
Eaton, 2008; Feinstein et al., 2011; Franch-Marro et al., 2008; Xia et al.,
2013b; Zhong et al., 2012). Third, young adult Vps35-heterozygote
(Vps35+/m) mice display lower bone-mass with reduced bone forma-
tion and increased bone resorption (Xia et al., 2013b). RANKL (receptor
activator of nuclear factor kappa-B ligand) signaling is increased and
sustained in Vps35-deﬁcient bone marrow macrophages (BMMs),
resulting in an increased OC formation and bone resorption (Xia et al.,
2013b). While this study has pointed to the importance of hyper-re-
sorptive OCs for the osteoporotic deﬁcit in Vps35+/m mice, the reduced
bone formation may also have a critical role in this deﬁcit. However, it
remains unclear the exact role of VPS35/retromer and the functional
signiﬁcance of VPS35/retromer regulation of PTH1R in OB-lineage cells.
PTH1R, a receptor of PTH, is an essential regulator of not only calci-
um–phosphorus metabolism, but also bone remodeling (Cheloha et al.,
2015; Vilardaga et al., 2012). Intermittent treatmentwith human recom-
binant PTH(1–34) promotes recruitments of both OB and OC and a net
bone-gain; but continued treatment leads to more OC activation with a
net bone-loss (Cheloha et al., 2015; Vilardaga et al., 2012). It is of consid-
erable interest to investigate howPTH(1–34) activation of PTH1R results in
such complexmetabolic effects. PTH(1–34) activation of PTH1R stimulates
adenylate cyclase (AC)-mediated cAMPproduction byGαs and increases
PLC-mediated [Ca2+]i (cytosolic free Ca2+ concentration) by Gαq
(Cheloha et al., 2015; Vilardaga et al., 2012). These G-protein mediated
signaling events, so called cell surface or canonical GPCR (G-protein
coupled receptor) signaling, contribute to the complex metabolic effects
induced by PTH (Vilardaga et al., 2012; Whalen et al., 2011). However,
recent studies have found thatβ-arrestin serves as amultifunctional scaf-
folding protein linking the PTH1R to signaling endosomes independent
of the cell surface or canonical GPCR pathway, and thus called endosomal
or non-canonical GPCR signaling, which are also important for the com-
plexmetabolic effects (Vilardaga et al., 2012;Whalen et al., 2011). Exact-
ly how both PTH-induced cell surface and endosomal signaling events
are involved in the complex metabolic functions, and how both path-
ways are regulated and/or terminated, remain poorly understood.
Here, we provide evidence that VPS35 in OB-lineage cells is necessary
for maintaining bonemass. Mice that selectively knock out VPS35 inma-
ture OBs, Vps35Ocn-Cre, as that of Vps35+/−, displayed reduced bone-
mass. However, PTH(1–34) treatments diminished such an osteoporotic
deﬁcit in both Vps35Ocn-Cre and Vps35+/−mutant alleles. In addition, a
more dramatic trabecular bone-gain response to PTH(1–34) was detected
in both Vps35mutant alleles, as compared with that of control mice. The
increased bone-gain response might be due to an impaired PTH(1–34)-
driven catabolic response or bone resorption. Further mechanistic stud-
ies showed that VPS35 in OB-lineage cells is required to turn off PTH(1–
34)-signaling. Such a negative regulation of PTH(1–34) signaling (in partic-
ular, the endosomal signaling) is likely due to VPS35 promotion of PTH(1–
34)-induced PTH1R translocation to the Golgi apparatus as well as VPS35
interaction with an inhibitor of PP1 phosphatase, PPP1R14C. This nega-
tive regulation of PTH(1–34)-driven endosomal signaling appeared to be
crucial for PTH(1–34)-induction of catabolic response. Taken together,
these results demonstrate a critical role for osteoblastic VPS35 to de-reg-
ulate PTH1R signaling, reveal a mechanism underlying VPS35 suppres-
sion of PTH1R-driven endosomal signaling, and provide insights into
PTH(1–34)-induced catabolic response and adequate bone remodeling.
2. Materials and Methods
2.1. Reagents and Animals
Rabbit polyclonal anti-VPS35 antibody was generated using the anti-
gen of GST-VPS35D1 fusion protein as described previously (Wen et al.,2011). Rabbit polyclonal antibodies, including pCREB (#9198S, Cell Sig-
naling), pErk1/2 (#4370S, Cell Signaling), Erk1/2 (#9102S, Cell Signaling),
pAkt (#4060P, Cell Signaling), Akt (#4691S, Cell Signaling), pSmad1/5/8
(Cell Signaling), PTH1R (PRB-630P-100, Covance), mCherry (ab183628,
Abcam), EEA1 (ab2900, Abcam), PPP1R14A (ARP63944, Aviva Systems
Biology), and PPP1R14C (AP10151b, Abgent) antibodies, were used.
Mouse monoclonal antibodies, including Flag (F1804, Sigma), V5
(V8012, Sigma), GM130 (BD Bioscience), and Rat anti-LAMP1 (DSHB) an-
tibodies were used. Secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories, Inc. PTH(1–34) (human) was obtained
from Bachem (H-4835). 1α, 25-Dihydroxyvitamin D3 and Forskolin was
obtained from SIGMA (D1530 and F6886). Other chemicals and reagents
used in this study were of analytical grade.
Vps35+/−mice (heterozygotes of Vps35mutantmice) are generated
by injection of mutant embryonic stem (ES) cells obtained from Bay Ge-
nomics as described previously (Wen et al., 2011). Vps35f/f mice were
generated as described previously (Tang et al., 2015b). The Ocn-Cre
mice were kindly provided by Dr. Tom Clemens (Johns Hopkins Medical
School). Vps35Ocn-Cre mice were generated by crossing Vps35f/f with
Ocn-Cre mice. Mice in C57BL6 background (N10 generations) were
maintained on a standard rodent diet (Harlan Tekled S-2335). Control lit-
termates were processed in parallel for each experiment. The Vps35mu-
tation was conﬁrmed by genotyping using polymerase chain reactions
(PCR) and by Western blot analysis as described previously (Wen et al.,
2011) (Tang et al., 2015b). All experimental procedures were approved
by the Institutional Animal Care andUse Committee at Augusta Universi-
ty (previously called Georgia Regents University), according to US Na-
tional Institutes of Health guidelines.
2.2. Plasmids and Lentiviruses
ThemiRNA-Vps35 expression vectorwas generated by the BLOCK-iT
Lentiviral miR RNA expression System (Invitrogen, Carlsbad, CA) ac-
cording to the manufacturer's instruction as previously described (Liu
et al., 2012; Wang et al., 2012; Wen et al., 2011; Xia et al., 2013b; Zhu
et al., 2007). The target sequences, 5′-AGGTGTAAATGTGGAACGTTA-3′
(for miRNA-Vps35), 5′-GGTACATCTATTTCTATGAAA-3′ (for shRNA-
Vps35) and 5′-GCTGCGAGGAAGAAGAAATGC-3′(for shRNA-
PPP1R14C) were designed using web-based Block-iT program
(Invitrogen) and subcloned into pcDNA 6.2-GW/EmGFP-miR
(Invitrogen) and pLV-shRNA (Biosettia) vectors, respectively. The
PTH1R-mCherry expression plasmid was generated by fusion of the
mCherry to the C-terminus of the RT-PCR ampliﬁed homo PTH1R
(NM_000316, remove the stop codon, include signal peptide, 1779 bp)
in a mammalian expression vector under control of the CAG promoter.
PPP1R14C-V5 and GST-PPP1R14C plasmids were purchased from
DNASU (HsCD00435544 and HsCD00734708). The authenticity of all
constructs was veriﬁed by DNA sequencing.
The lentiviruswas packaged by co-transfection of pLV-shRNA-Vps35
or pLV-shRNA-PPP1R14C with virus packaging plasmids into human
embryonic kidney (HEK) 293 T cells using the PEI transfection method.
In brief, 15 μg DNA mixture (7.5 μg pLV-shRNA-Vps35 or pLV-shRNA-
PPP1R14C and 7.5 μg of pVSVG, PLP1, and PLP2, each at 2.5 μg, for one
100-mm dish) were prepared in serum-free DMEM, 7.5 μl PEI was
added to the diluted DNA and mix immediately by vortexing or pipet-
ting. The volume of PEI used is based on a 3:1 ratio of PEI (μg): total
DNA (μg). The DNA/PEI mixture was added to cells after incubation
20 min at room temperature. 48 h after transfection, the viral superna-
tants were harvested and concentrated by centrifugation (25,000 rpm
for 90 min at 4 degree).
2.3. PTH(1–34) Treatments
For in vivo experiments, P50 old Vps35+/+ and Vps35+/−malemice
or control (Vps35f/f) and Vps35Ocn-cre mice were administered once
daily injection of hPTH(1–34) 50 μg/Kg, or vehicle (0.9% sodium chloride),
47L. Xiong et al. / EBioMedicine 9 (2016) 45–605 days per week for a total of 5 weeks. Mice were sacriﬁced 24 h after
the last injection. The serum and bone samples were collected.
For in vitro experiments, 100 nM PTH(1–34) was added to the
growth medium at every medium change. For cell signaling and im-
munoﬂuorescence staining experiments, cells were serum starved
overnight and stimulatedwith PTH(1–34) for indicated time in the ﬁg-
ure legend.2.4. In Vitro BMSC Culture, Cell Line Culture and Transient Transfection
Whole bone marrow cells were ﬂushed from long bones of WT and
Vps35+/m mice and plated on 100 mm tissue culture plates in DMEM
containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
(P/S). Plates were replaced with fresh culture medium every 3 days.
After 7 days, passaging cells by trypsin digestion, 1 ∗ 104/cm2were plat-
ed for PTH treatment experiments.
MC3T3-E1 cells were maintained in Dulbecco modiﬁed Eagle medi-
um supplemented with 10% fetal calf serum, and 100 units/ml of peni-
cillin G and streptomycin (Gibco). For examining PTH signaling
experiments, cells was infected with lentiviruses expressing scramble
control (GFP), shRNA-Vps35 (BFP or GFP) or shRNA-PPP1R14C (GFP)
for 1 week and puriﬁed by Fluorescent activated cell sorting (FACS).
The ﬂuorescence-positive cells (GFP+ cells for Scramble control or
shRNA-PPP1R14C; BFP+ cells for shRNA-Vps35; both GFP+ and
BFP+ cells for shRNA-Vps35 + shRNA-PPP1R14C or shRNA-
Vps35 + Scramble control) were cultured and used for experiments.
For transfection, cells were plated at a density of 106 cells per 10-cmcul-
ture dish and allowed to grow for 12h before transfection using Lipofec-
tamine™ 2000 (Invitrogen). 48 h after transfection, cells were subjected
to immunostaining analysis.2.5. Osteoclast Precursors-osteoblast Co-cultures Assay
Primary osteoblast culture were prepared from 1-month-oldWT/
Vps35+/− or 3-month-old OcnCre/Vps35Ocn-CKO mice long bones.
Brieﬂy, small bone pieces were incubated in collagenase solution to
remove all remaining soft tissue and adhering cells, then transfer to
60 mm culture dishes containing DMEM medium supplemented
with 10% FBS, 1% penicillin/streptomycin, 10 mM β-glycerophos-
phate and 50 μM L-ascorbic acid-2-phosphate. Replace culture medi-
um three times per week. Bone cells will start to migrate from the
bone chips after 3–5 day. After two weeks, the monolayer is
trypsinized by incubating the cells with trypsin solution. Cells were
cultured in 60 mm dishes with α-MEM mineralizing medium con-
taining 10% FBS, 1% penicillin/streptomycin, 2.5 mM β-glycerophos-
phate and 10−8 M Vitamin D3 for 2 days prior to co-culture with
osteoclast precursors.
To isolate osteoclast precursors, total bone marrow is ﬂushed from
the long bones (femur and tibia) of 3-month-old WT mice with ice-
cold α-MEM and plated on 100 mm culture dishes in α-MEM contain-
ing 10% FBS and 10 ng/ml recombinantM-CSF. Cells were incubated at
37 °C with 5% CO2 overnight. Nonadherent cells were harvested and
subjected to Ficoll-Hypaque gradient centrifugation for puriﬁcation of
BMMs. Cells were placed onto pre-sterilized glass coverslips in the 12-
well plates in α-MEM containing 10% FBS and 10 ng/ml recombinant
M-CSF. After a few days, the coverslips containing osteoclastic cells
were seeded ontomineral thin ﬁlms aboveWT or Vps35-KD osteoblasts
already plated on the 100 mm culture dishes. For the sham control
group, cells were cultured in α-MEM medium supplemented with 10%
FBS, 1% penicillin/streptomycin and 2.5 mM β-glycerophosphate.
Other groups were treated with PTH(1–34) intermittently (iPTH)
(100 nM, 1-h per day) or continually (cPTH)(100 nM), or Vitmin
D3(10−8 M, daily change with fresh medium). The co-cultures were
grown for 10–12 days and prepared for TRAP staining.2.6. Immunoﬂuorescence Staining and Confocal Imaging Analysis
MC3T3-E1 cells plated onto coverslips were ﬁxed with 4% parafor-
maldehyde at room temperature for 20min, permeabilized in 0.15% Tri-
ton X-100 for 8 min, and then subjected to co-immunostaining analysis
using indicated antibodies. The stained cells were washed 3 times with
PBS andmountedwith VECTASHIELD (H-1200; Vector Laboratories) for
imaging analysis by Zeiss LSM 510 Upright Confocal Microscope with
405, 488, 561 and 633 lasers (Carl Zeiss; LSM 510 software) at room
temperature. A Plan-Apochromat 63X/ 1.40 oil DIC M27 objective lens
(Carl Zeiss) was used with Immersol 518 N (Carl Zeiss). The acquired
8-bit RGB images were exported to TIFF ﬁles with the LSM510 viewer
software (Carl Zeiss). Photoshop software CS5 (Adobe) was used to ad-
just the brightness. Figures were constructed in Illustrator version CS5
(Adobe).
For ﬂuorescent quantiﬁcation, morphometric measurements of im-
ages were performed using NIH ImageJ and ZEN (Carl Zeiss) software.
Two channels (red and green) were selected for colocalization analysis.
Single labeled control samples (red or green) were prepared to accu-
rately set the crosshairs. The controls were imaged with the same mi-
croscope setting as the double or triple labeled experimental samples.
The pixel distribution of a red-only or a green-only population was ex-
amined, and the horizontal or vertical crosshair was set just above this
population (The threshold was between 40–60, based on different ex-
periments). The quadrants represent pixels that have high green and
low red intensities, or high red and low green intensities were consider
false colored. The quadrant represents pixels with high intensity levels
in both green and red are considered to be co-localized.
2.7. Protein Extraction and Western Blot Analysis
For cell signaling experiments,MC3T3 or BMSCswere serum starved
overnight and stimulated with PTH(1–34) (100 nM) or epinephrine
(300 nM) for indicated time in the ﬁgure legend, and the total protein
was extracted with lyses buffer, which contained 50 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1%(v/v) Triton X-100, 0.1% SDS, 0.5%
deoxycholate and 1 mM EDTA, supplemented with protease inhibitors
(1 μg/ml leupeptin and pepstatin, 2 μg/ml aprotinin and 1 mM PMSF)
and phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4). The pro-
tein was propelled by western blot analyses.
2.8. Measurement of cAMP Production
Levels of cAMP were measured using a commercially available
cAMP complete ELISA kit (Enzo Life Sciences, Farmingdale, NY,
USA). MC3T3 cells or BMSCs were plated in 12-well plates with the
same cell density. Cells were serum starved overnight and stimulat-
ed with PTH(1–34) (100 nM) or Forskolin (10 μM) for the indicated
time. Then, cells were lysed for 10 min with 0.1 M HCl, centrifuged
at 600 g at room temperature. The supernatant were assayed as de-
scribed by the manufacturer.
2.9. Micro-computed Tomography (μCT)
The μCT analyses were carried out as described previously (Xia et al.,
2013a; Xia et al., 2013b). In brief, micro-architecture of the distal trabec-
ular bone and mid-shaft cortical bone of the femurs from 3-month or
older mice were measured by Scanco μCT 40 (Scanco Medical AG,
Brüttisellen, Switzerland).
The scan of the trabecular bone was performed from the growth
plate, and consisted of 200 slices (each slice was 12 μm in thickness).
The 3-D reconstruction was performed using all the outlined slices. No
cortical bone was included in this analysis. Data was obtained on bone
volume (BV), total volume (TV), BV/TV, bone density, trabecular num-
ber and connectivity.
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femur and consisted of 25 slices (each slice was 12 μm in thickness).
There was no trabecular bone in these images at the mid-shaft. Cortical
bone was thresholded at 329, and the 3-D reconstruction was per-
formed on all 25 slices. Data was obtained on BV, TV, BV/TV, bone den-
sity, and cortical thickness.
2.10. Bone Histomorphometric Analysis
Bonehistomorphometric analyseswere carried out as previously de-
scribed (Cui et al., 2010; Xia et al., 2013a; Xia et al., 2013b; Zhou et al.,
2008; Zhou et al., 2006). In brief, mouse tibia and femurs were ﬁxed
overnight in 10% buffered formalin, decalciﬁed in 14% EDTA, embedded
in parafﬁn, sectioned, and subjected for H & E and TRAP staining analy-
ses, whichwere counter stained by fast green. Bone histomorphometric
perimeters were determined by measuring the areas situated at least
0.5 mm from the growth plate, excluding the primary spongiosa and
trabeculae connected to the cortical bone.
2.11. Measurements of Serum Levels of Osteocalcin, PYD, and Calcium
Mouse serum samples were collected and allowed to clot for 30min
and then centrifuged for 10 min at 3000 rpm. Serum was frozen at
−80 °C until use. Mouse osteocalcin Elisa kit (Biomedical Technologies,
Inc.), METRA SerumPYDRIA kit (QUIDEL Corporation), and CalciumDe-
tection Kit (Abcam) were used to measure mouse serum levels of
osteocalcin, PYD and calcium as described previously (Cui et al., 2010;
Xia et al., 2013b; Zhou et al., 2006). All the assays were carried out per
the instructions. All the samples were measured in duplicate, the ODs
measured after reactions were converted to osteocalcin/PYD/calcium
concentration using their standard curves, and values were subjected
to statistical analysis.
2.12. RNA Isolation and Real Time-PCR
Primary cultured BMSCs orMC3T3were treatedwithout PTH (Sham
control) andwith PTH(1–34) intermittently (iPTH) (100 nM, 1-h per day,
for 6 days) or continually (cPTH)(100 nM, daily change with fresh me-
dium containing PTH(1–34)). For short time course to conﬁrm the tran-
script stability of RANKL or OPG (Fu et al., 2002), BMSCs or MC3T3
were treat with PTH(1–34) (100 nM) for 0, 1, 2, 4, 6 and 12 h. Total
RNA was isolated from BMSCs or MC3T3 by Trizol extraction
(Invitrogen, Carlsbad, CA, USA). Q-PCRwas performedwith a Quantitect
SYBR Green PCR Kit (Bio–Rad), according to the manufacturers's in-
struction, and with a Real-Time PCR System with analytical software
(Opticon Monitor 3). The following primers were used: Osteocalcin,
5′-CTGGCTGCGCTCTGTCTCT-3′ and 5′-TGCTTGGACATGAAGGCTTTG-
3′; RANKL, 5′-ATCCCATCGGGTTCCCATAA-3′ and 5′-
TCCGTTGCTTAACGTCATGTTAG-3′; OPG, 5′-
GGCCTGATGTATGCCCTCAA-3′ and 5′-GTGCAGGAACCTCATGGTCTTC-
3′; MEPE, 5′-GCAGGTGGGAGCCTTGTG-3′ and 5′-
GGCTGCCGGCATTAATTCT-3′. β-actin primers (5′-
AGGTCATCACTATTGGCAACGA-3′ and 5′-CATGGATGCCACAGGATTCC-
3′) were used for normalization.
2.13. Co-immunoprecipitation (Co-IP)
HEK293T cells were maintained in Dulbelcco's modiﬁed Eagle's me-
dium supplementedwith 10% (vol/vol) fetal bovine serum (Invitrogen).
Transient transfection was performed with PEI. Transfected cells were
harvested after 48 h in the following buffer: 50 mM Tris-HCl(pH 7.5);
150 mM sodium chloride; 1% Nonidet P40; 0.5% sodium deoxycholate,
with protein inhibitor cocktail (Roche). Immunoprecipitation was per-
formed with a 1/100 dilution of a rabbit polyclonal mCherry antibody
or a mouse monoclonal V5 antibody against PTH1R-mCherry or
PPP1R14C-V5. Western blotting was performed using the ECLprocedure according to the manufacturer's instructions (Bio–Rad),
with a mouse monoclonal Flag antibody to detect the co-immunopre-
cipitation Flag-Vps35 or anti-mCherry rabbit polyclonal antibody for
PTH1R-mCherry proteins.
2.14. GST Pull-down Assays
GST and GST-PPP1R14C fusion proteins were expressed in IPTG-
stimulated (1 mM ﬁnal concentration) BL21 Escherichia coli. Bacteri-
al cell lysates were allowed to bind to the glutathione-Sepharose 4B
beads (GE Health Sciences). Flag-Vps35 and PTH1R-mCherry pro-
teins were synthesized in HEK293 cells. The GST pull-down assays
was performed by incubation GST beads with each extract for 1 h
at 4 with constant mixing. After washing GST beads ﬁve times with
PBS and eluting proteins with SDS sample buffer, western blots
were performed.
2.15. Statistical Analysis
All data were expressed as mean± SD. For in vivo studies, 5–6mice
per genotype per assay were used. For in vitro cell biological and bio-
chemical studies, each experiment was repeated 3 times. 10–50 cells
were quantiﬁed for immunostaining analyses. The signiﬁcance level
was set at P b 0.05, the Student t-test, two-way ANOVA and post-hoc
test (GraphPad Prism 5) were used.
3. Results
3.1. PTH(1–34) Stimulation of PTH1R-VPS35 Interaction and Their Transloca-
tion to the Golgi in MC3T3 Cells
In light of the observations that VPS35 regulates PTH1R's trafﬁcking
and signaling in HEK293 cells (Feinstein et al., 2011), and both VPS35
and PTH1R are highly expressed in OBs (Simmonds and Kovacs, 2010;
Vilardaga et al., 2012; Xia et al., 2013b), we speculate a crucial role for
VPS35 to play in regulating PTH1R's trafﬁcking, signaling, and function
in OB-lineage cells. To test this speculation, we ﬁrst examined exoge-
nous PTH1R's trafﬁcking in control and Vps35-deﬁcient MC3T3 cells,
an osteoblastic cell line that responses to PTH(1–34) stimulation (Issack
et al., 2007;Moriya et al., 2015; Schiller et al., 1999). A plasmid encoding
PTH1R-mCherry fusion protein was generated, which is a similar fusion
protein as PTH1R-EGFP that is often used in the literature to image
PTH1R's distribution (Feinstein et al., 2011) (Fig. S1A). When expressed
inMC3T3 cells, the PTH1R-mCherry displayed a cell surface and vesicle-
like punctae distribution pattern, which could be recognized by anti-
PTH1R (Fig. S1B). Upon PTH(1–34) stimulation, the PTH1R-mCherry ex-
pressing cells, but not controls, exhibited an increase in cAMP (Fig.
S1C) and phospho-CREB (Fig. S1D–S1E), demonstrating the sufﬁciency
and speciﬁcity of PTH1R-mCherry in mediating PTH signaling. We
then used this fusion protein to examine its co-localization with endog-
enous VPS35 in MC3T3 cells. Very few punctae with PTH1R-VPS35 co-
localization was detected in the basal culture condition (Fig. 1A). How-
ever, upon PTH(1–34) stimulation, their co-localization was increased in
a time-dependent manner: peaked at 30 min, but declined at ~45 min
of stimulation (Fig. 1A–B). The increase in PTH1R-VPS35 complex for-
mation by PTH(1–34) was veriﬁed by co-immunoprecipitation analysis
(Fig. 1C, D). It is noteworthy that the PTH1R-VPS35 complex was
translocated to perinuclear organelles in response to PTH(1–34) stimula-
tion (Fig. 1A, E), which we determined to be the Golgi apparatus by co-
localization with the Golgi marker GM130 (Fig. 2A). The time course of
PTH(1–34)-induced PTH1R-VPS35 co-localization correlated well with
that of PTH1R-VPS35 translocation to the Golgi (Fig. 1A–B, E), but
slower to decline, as compared with the time course of cAMP signaling
(Fig. 1B). These results demonstrate a time-dependent increase of
PTH1R interaction with VPS35 as well as PTH1R translocation to the
Golgi by PTH(1–34), in line with the view for PTH1R as a cargo of
Fig. 1. PTH(1–34)-increase of PTH1R interactionwith VPS35 and PTH1R translocation to the TGN. (A–B)VPS35-PTH1R co-localization inMC3T3 cellswas increased by PTH(1–34) stimulation.
MC3T3 cells were transfected with PTH1R-mCherry, and then stimulated with PTH(1–34)(100 nM) for 0, 15 min, 30 min and 45 min. Cells were ﬁxed and immunostained with indicated
antibodies. (A) Representative images. Imagesmarkedwithwhite squares were ampliﬁed and shown in right top images. Bar, 10 μm. (B) Quantiﬁcation analysis of data from A using ZEN
and ImageJ as described in Materials and Methods. The co-localization index of PTH1R-mCherry with VPS35 was determined by the measurement of overlapped signal (yellow
ﬂuorescence) over total VPS35 signal. The means ± SEM (n = 20 cells from 3-different assays) were presented. *, P b 0.05. (C–D) VPS35-PTH1R co-immunoprecipitation was
increased by PTH(1–34). HEK293T cells were transfected with indicated plasmids. 48-h post transfection, cell lysates (~500 μg) were immunoprecipitated by anti-mCherry antibody (for
PTH1R) and anti-non-speciﬁc IgGs (a non-speciﬁc control). The resulting lysates were subjected to Western blot analysis using indicated antibodies. ~50 μg of cell lysates were used as
inputs. Note that a weak mCherry signal was detected in the non-speciﬁc IgG immunoprecipitates in 1C, which might be due to a non-speciﬁc association of mCherry proteins with
the IgG. The data presented is a representative of 3-independent experiments. The data were quantiﬁed and shown in right as means ± SEM. *, P b 0.05. (E) The distance (×10 μm) of
Vps35-PTH1R co-distribution puncta to the nuclear membrane were presented.
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also in the osteoblastic cell line.
3.2. Reduced PTH(1–34)-driven PTH1R Translocation to the Golgi, But In-
creased PTH(1–34)-driven Signaling, in Vps35-deﬁcient MC3T3 and Primary
OB-lineage Cells
We next examined VPS35's function in PTH(1–34)-induced PTH1R
translocation to the Golgi. This event required VPS35 expression in
MC3T3 cells, as PTH(1–34)-induced PTH1R translocation to Golgi was de-
tected in control cells, but reduced in Vps35-KD (knock-down by
miRNA-Vps35)MC3T3 cells (Fig. 2A–B).We then tested if PTH1R distri-
bution in endosomeswas increased in Vps35-KD cells, asmost retromer
cargos do. PTH1R in EEA1+ early endosomes was unchanged in re-
sponse to PTH(1–34) stimulation or Vps35-deﬁciency (Fig. 2C–D). How-
ever, PTH1R in LAMP1+ late endosomes/early lysosomes wasincreased in PTH(1–34)-stimulated Vps35-KD MC3T3 cells (Fig. 2E–F).
In line with this observation, PTH1R-mCherry was less stable when
Vps35 was suppressed, with a shorter half-live (~4 h) in Vps35-deﬁ-
cient HEK293 cells than that of control cells (~8 h of half live)(Fig. S2).
These results thus demonstrated the necessity of VPS35 in retrieval of
PTH1R from late endosomes/lysosomes to the Golgi and thus
preventing PTH1R degradation.
To investigate functional signiﬁcance of VPS35-regulation of PTH(1–
34)-induced PTH1R translocation,we examined PTH(1–34)-driven signal-
ing dynamics in control and Vps35-KD MC3T3 cells (by infecting lenti-
virus encoding shRNA-Vps35). MC3T3 cells infected with lentiviruses
of shRNA-Vps35 exhibited ~80% reduction of endogenous Vps35's ex-
pression (Fig. 3C). PTH(1–34)-induced signaling events include cell sur-
face (such as Gαs-mediated cAMP induction) and endosomal (such as
phosphorylations of Erk1/2 and Akt) pathways, and both are important
for PTH functions (Vilardaga et al., 2012). As shown in Fig. 3A, the cAMP
Fig. 2. Impaired PTH1R trafﬁcking to TGN in VPS35-deﬁcient MC3T3 cells. Co-immunostaining analysis of PTH1R-mCherry with GM130 (a marker for Golgi), EEA1 (a marker for early
endosomes) or Lamp1 (a marker for late endosomes and early lysosomes) in control and Vps35-KD (by its miRNA) MC3T3 cells that were treated with or without PTH(1–34) (100 nM,
30 min). (A, C, and E) Representative images. Images marked with white squares in (A) were ampliﬁed and shown in middle images. Bar, 10 μm. (B, D, and F) Quantiﬁcation analysis
of data from A, C and E using ZEN and ImageJ as described in Materials and Methods. The co-localization index of PTH1R-mCherry with indicated markers (GM130, EEA1 and LAMP1)
was determined by the measurement of overlapped signaling (yellow ﬂuorescence) over total PTH1R-mCherry signal. The values of means ± SD (n= 20 cells from 3-different assays)
were show. *, P b 0.05.
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pendent manner: increased at 5-min, peaked at 15-min, and declined
at 30 min after PTH(1–34) stimulation. In Vps35-KD MC3T3 cells, the
cAMP levels were further increased, and the time course was sustained
in response to PTH(1–34), compared with that of control MC3T3 cells
(Fig. 3A). This effect was speciﬁc, as the cAMP levels induced by
forskolin, an activator of adenylate cyclase (AC), were slightly lower in
Vps35-KD MC3T3 cells than that of controls (Fig. 3B). These results
thus demonstrate a speciﬁc inhibitory role of VPS35 in PTH(1–34)-in-
duced cAMP/cell surface signaling.We then examined PTH(1–34)-induced phosphorylations of Erk1/2
(pErk1/2) and Akt (pAkt), in addition to pCREB (a downstream of
cAMP-PKA pathway). Interestingly, they were all increased, and their
time courses were also sustained in PTH(1–34)-stimulated Vps35-KD
MC3T3 cells, as compared with that of controls (Fig. 3C–D). The total
protein levels of Erk1/2, Akt, and CREB were unchanged in Vps35-KD
cells (Fig. 3C). However, the basal levels of pCREB, pErk1/2, and pAkt
in Vps35-KD MC3T3 cells appeared to be higher than those in control
cells (Fig. 3C). After normalization with their basal levels, PTH(1–34)-in-
duced pCREB, pErk1/2, and pAkt remained to be sustained as compared
Fig. 3. Increased and sustained PTH(1–34)-driven signaling inVps35-deﬁcientMC3T3 cells. Cellswere serumstarved overnight and stimulatedwith PTH(1–34)(100 nM) or Forskolin (10 μM)
for the indicated time. For cAMP assay in (A–B), cells were lysedwith 0.1MHCl and centrifuged, the supernatant were assayed by using a cAMP ELISA kit. ForWestern blot analyses in (C–
D), cell lysateswere subjected toWestern blot analyses using indicated antibodies. Representative blots were shown in C, and quantiﬁcation analyses (by ImageJ software) of the data in C
were shown in D. The values of mean ± SD from 3 separate experiments were shown. *, P b 0.05.
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MC3T3 cells plays a negative role in regulating PTH(1–34)-driven signal-
ing, both cAMP induction and phosphorylations of CREB, Erk1/2, and
Akt.
PTH(1–34)-increase of pCREB in Vps35-KD MC3T3 cells was further
conﬁrmed by immunostaining analysis. The pCREB was mainly distrib-
uted in the nuclei, which was slightly increased by PTH(1–34) (Fig. S3A–
B), but was obviously increased in the nuclei of Vps35-KDMC3T3 cells,
compared with control MC3T3 cells after PTH(1–34) stimulation (Fig.
S3A, S3C). This event was speciﬁc, as it was not increased in scramble
RNAi expressing MC3T3 cells (Fig. S3A, S3C). Interestingly, a
synergistical elevation in pCREB level was detected in Vps35-KD
MC3T3 cells expressing PTH1R-mCherry, comparedwith the expression
of PTH1R-mCherry or Vps35-KD alone (Fig. S3C). Taken together, these
results indicate that VPS35 plays a critical role in deregulating PTH1R
signaling, both cell surface and endosomal pathways, implicating
VPS35 in PTH(1–34)-induced functions.
3.3. Impairment in PTH(1–34)-driven Catabolic Response, but Enhancement
in PTH(1–34)-induced Anabolic Response, in Vps35
+/− BMSCs and Mice
We next investigated if VPS35 plays a role in regulating PTH(1–34)-
driven anabolic and/or catabolic responses. First, primary cultured
BMSCs derived from Vps35+/+ and +/− mice were treated with
PTH(1–34) in two settings (Fig. 4A). One is intermittent treatment of
PTH(1–34) (iPTH) (100 nM, 1 h/day, for 6 days), which induces anabolic
response; and another one is continued treatment (cPTH)(100 nM,
24 h/day, for 6 days) that stimulates catabolic reaction (Fig. 4A)
(Huang et al., 2004; Schiller et al., 1999). As shown in Fig. 4B, iPTH treat-
ment resulted in a slight increase in expression of osteocalcin and
RANKL in both Vps35+/+ and +/− BMSC cultures, compared to shamcontrols. No difference was detected between Vps35+/+ and +/− cul-
tures in responses to control or iPTH treatments (Fig. 4B–C), suggesting
normal basal and anabolic-like responses in the mutant culture. In con-
trast, the catabolic response induced by cPTH treatment was different
between Vps35+/+ and +/− BMSC cultures (Fig. 4B–C). The cPTH treat-
ment was capable to induce a catabolic-like response (e.g., decreased
expression of osteocalcin and OPG, but increased RANKL-expression)
in Vps35+/+ cultures (Fig. 4B–C), but failed to do so in Vps35+/− cul-
tures (Fig. 4B). The expression of OPG, osteocalcin, and MEPE (matrix
extracellular phosphoglycoprotein), but not RANKL, was markedly ele-
vated in Vps35+/− cultures with cPTH stimulation (Fig. 4B), resulting
in a decreased ratio of RANKL over OPG in Vps35+/− BMSCs following
cPTH-stimulation, as compared with that of Vps35+/+ controls (Fig.
4C). Together, these results suggest that Vps35-deﬁciency in OB-lineage
cells causes aweak increase in PTH(1–34)-driven anabolic response, but a
major decrease in PTH(1–34)-induced catabolic response.
Second, we examined VPS35's function in PTH(1–34)-induced cata-
bolic response by an in vitro osteoclastogenesis co-culture assay. In
this assay, wt-BMMs were co-cultured with wt-OBs or Vps35+/− OBs
in the absence of exogenous RANKL, but presence of control (PBS),
iPTH, or cPTH stimulations. At day 7 of the co-culture, cells were stained
with TRAP, and TRAP+ MNCs (multi-nuclei cells)(an indicator for oste-
oclastogenesis)were quantiﬁed. As shown in Fig. 4D–E, iPTH treatments
induced comparable numbers of TRAP+MNCs betweenwt- and Vps35-
deﬁcient OB co-cultures. However, cPTH treatments resulted in a signif-
icant less TRAP+MNCs formed in Vps35-deﬁcient OBs than those inwt-
OBs co-cultures (Fig. 4D–E). These results thus provide additional evi-
dence for an impaired cPTH-driven catabolic response in Vps35+/−
OB-lineage cells.
Third, we tested PTH(1–34)'s function in Vps35+/+ and +/− mice.
PTH(1–34) was applied to Vps35+/+ and +/− mice at age of P50 (sc,
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sacriﬁced, and their femur bone and serum samples were collected
and subjected for further analyses (Fig. S4A). Measuring serum levels
of pyridinoline (PYD)(a marker for bone resorption or catabolic re-
sponse of PTH) showed an increase in Vps35+/+, but not in Vps35+/−,
mice in response to PTH(1–34) treatment, compared with that of vehicle
controls (Fig. S4I), supporting the view for an impairment in PTH(1–34)-
induced catabolic response in Vps35+/− mice. In contrast, a moredramatic increase in serum osteocalcin levels (a bone formation mark-
er) was also detected in PTH(1–34)-injected Vps35+/− mice than that
in Vps35+/+ controls (Fig. S4J), in line with the notion for an increased
anabolic response. In agreement with these views were observations
from microCT (μCT) analysis, which showed a more dramatic increase
in trabecular bone volumes in PTH(1–34)-injected Vps35+/− mice than
that in Vps35+/+ littermate controls (Fig. S4B–S4H). The osteoporotic
deﬁcit in young adult Vps35+/− mice was diminished by PTH(1–34)
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(TB. Th.), numbers (TB. N.), and connectivity (CD) revealed that
PTH(1–34) increased TB.Th. in both Vps35+/+ and +/− mice (Fig. S4F),
but reduced TB.N. and CD only in Vps35+/+, but not +/− mice (Fig.
S4G–S4H). Taken together, Vps35+/− mice showed more dramatic
PTH(1–34)-induced anabolic response, but an impaired catabolic re-
sponse, demonstrating a necessity of VPS35 for PTH(1–34)-induced cata-
bolic response in vivo.
3.4. Enhanced PTH(1–34)-increased Anabolic Response With an Impaired
Catabolic Response by Selective Deletion of VPS35 Gene in Mature OB-line-
age Cells
VPS35 is expressed in both OB- and OC-lineage cells (Xia et al.,
2013b). We thus asked whether VPS35 in OB-lineage cells is required
for PTH(1–34)-induced catabolic response in vivo. To this end, we gener-
ated OB-selective Vps35 knocking out mice, Vps35Ocn-Cre, by crossing
the ﬂoxed allele (Vps35f/f) with the osteocalcin (Ocn)-Cre. VPS35 pro-
tein was selectively reduced in OB-lineage cells, but not BMMs, derived
from Vps35Ocn-Cre mice, compared with that of controls (Vps35f/f
mice)(Fig. S5C). As Vps35+/− mice (Xia et al., 2013b), Vps35Ocn-Cre
mice at young adult age (3-month old) had normal body weight (Fig.
S5A–S5B), but displayed osteoporotic deﬁcits, including decreased tra-
becular and cortical bone-mass and reduced serum osteocalcin level
(Fig. 5, and S5D–S5F). PTH(1–34) was then applied to Vps35Ocn-Cre and
control (Vps35f/f) mice at age of P50 (sc, 50 μg/kg, 5 times/wk) for
5 weeks as described in Fig. S4A. After PTH(1–34) injections, Vps35Ocn-
Cre mice showed more dramatic anabolic response, such as increases
in trabecular bone volumes and trabecular thickness (TB. Th.), as well
as the serum osteocalcin levels than those of control mice (Fig. 5A–F).
The catabolic response, viewed by increased serum PYD and calcium
levels, was detected in control, but not Vps35Ocn-Cre mice (Fig. 5G–H).
The osteoporotic deﬁcit in Vps35Ocn-Cre mice was also diminished by
PTH(1–34) treatment (Fig. 5).
Moreover, as Vps35-KDMC3T3 cells, PTH(1–34)-driven signalings, in-
cluding cell surface signaling (cAMP induction) and endosomal signal-
ing (pCREB, pErk1/2, and pAKT), were all increased, and their time
courses were sustained in BMSCs from Vps35Ocn-Cre mice, compared
with that of controls (Fig. 6A–C).
Furthermore, we examined osteocalcin, RANKL and OPG's expres-
sion in control (Vps35f/f) and Vps35Ocn-Cre BMSCs in response to
PTH(1–34) stimulation for a short time course (1, 2, 4, 6 to 12 h). As
shown in Fig. 6D, osteocalcin's transcripts were slightly elevated in
Vps35Ocn-Cre BMSCs, compared with those of controls, when PTH(1–34)
was present for more than 6-h. PTH(1–34)-induced RANKL's transcripts
were comparable between control and Vps35Ocn-Cre BMSCs (Fig. 6E).
However, OPG's transcripts were decreased in control cells, but in-
creased in Vps35Ocn-Cre BMSCs, in response to PTH(1–34) stimulations
(Fig. 6F). Thus, ratios of RANKL over OPG were much lower in PTH(1–
34)-stimulated Vps35Ocn-Cre BMSCs than those in control cells (Fig. 6G).
These results support the view for an impaired PTH(1–34)-driven cata-
bolic response in Vps35–deﬁcient OB-lineage cells.
Finally, we tested this view by examining osteoclastogenesis by the
co-culture assay:wt-BMMs pluswt-OBs or Vps35Ocn-Cre OBs in the pres-
ence or absence of iPTH(1–34) or cPTH(1–34) or vitamin D3 stimulations.Fig. 4. Reduced PTH(1–34)-driven catabolic response in Vps35-deﬁcient BMSCs andmice. (A) Int
and Vps35+/− mice (at age of 3-month old) were treated without PTH (Sham control) and
(cPTH)(100 nM, daily change with fresh medium containing PTH(1–34)). The total RNAs were
analysis of the mRNA levels of osteocalcin, MEPE, RANKL, and OPG. The values are normali
different experiments were presented. Data is determined by two-way ANOVA followed b
analysis of multiple nuclei cells (OCs) derived from BMMs co-culture with osteoblasts from
mineral thin ﬁlms above Vps35+/+ or Vps35+/− osteoblasts already plated on the 100 mm
penicillin/streptomycin, 2.5 mM β-glycerophosphate and 10−8 M Vitamin D3 (ﬁrst 2 day
(100 nM, 1-h per day) or continually (cPTH)(100 nM). The co-cultures were grown for
quantitative analyses of TRAP+ multinuclei cells (MNCs) over total cells are presented in E. Th
by two-way ANOVA *, p b 0.05, signiﬁcant difference.The iPTH(1–34) or vitamin D3 treatments induced comparable numbers
of TRAP+ MNCs between wt- and Vps35Ocn-Cre OB co-cultures (Fig.
6H–I). Again, cPTH(1–34)-induced TRAP+ MNCs were much less in
Vps35Ocn-cre OBs than those in wt-OBs co-cultures (Fig. 6H–I).
In aggregates, these results reconﬁrmed the necessity of VPS35 in
OB-lineage cells to maintain bone-mass, to deregulate PTH(1–34)-in-
duced cell surface and endosomal signaling, to promote PTH(1–34)-driv-
en catabolic response, and thus to prevent a large bone-gain by PTH(1–
34).
3.5. VPS35 Interaction With PPP1R14C, an Inhibitory Subunit of PP1
Phosphatase
To understand how VPS35 terminates PTH1R-mediated signaling,
we searched for additional VPS35/retromer binding partners.
PPP1R14C is one of the newVPS35/retromer binding partners identiﬁed
by subcellular fractionation of retromer complex inHela cells and prote-
omic analysis (Fig. 7A) (http://human.med.utoronto.ca/index.php). As
PPP1R14C is an inhibitory subunit of PP1 serine/threonine phosphatase
(Drgonova et al., 2010; Eto, 2009; Liu et al., 2002; Wenzel et al., 2007),
we speculate that VPS35may deregulate PTH1R signaling via its interac-
tion with PPP1R14C. To test this view, we ﬁrst veriﬁed VPS35's interac-
tion with PPP1R14C inMC3T3 cells by co-immunostaining analysis. The
endogenous PPP1R14C (revealed by the polyclonal anti-PPP1R14C anti-
body)was indeed co-localizedwith the exogenous GFP-VPS35 (Fig. 7B).
Their co-localization appeared to be speciﬁc, as it was not detected be-
tween GFP-VPS35 with endogenous PPP1R14A, a PPP1R14C-family
PP1 inhibitor (Fig. 7B–C). The anti-PPP1R14C antibodywas also speciﬁc,
as its immunostaining signal was abolished in cells knocking down of
PPP1R14C (PPP1R14C-KD) (Fig. S6). We next conﬁrmed VPS35 interac-
tion with PPP1R14C by co-immunoprecipitation analysis (Fig. 7D–E).
VPS35 was indeed detected in PPP1R14C-immunocomplex (Fig. 7D).
The VPS35-PPP1R14C interaction was also enhanced by PTH(1–34) stim-
ulation (Fig. 7D–I), but reduced by expression of PTH1R-mCherry (Fig.
7F–H). Moreover, we tested if VPS35 interaction with PPP1R14C is a di-
rect binding. The recombinantGST-PPP1R14C fusion proteinwas gener-
ated and subjected to an in vitro GST pull down assay. Indeed, VPS35
was detectable in the precipitates pulled down by GST-PPP1R14C, but
not GST (Fig. 7J), suggesting a direct interaction. Taken together, these
results support the view for PPP1R14C as a VPS35/retromer binding
partner in MC3T3 cells and implicate PPP1R14C's involvement in PTH
signaling.
3.6. PPP1R14C Interaction With PTH1R, Which is Increased by PTH(1–34)
Stimulation, but Suppressed by VPS35
Whereas PPP1R14C-VPS35 co-localization was reduced by PTH1R-
mCherry, a co-localization of PPP1R14C with PTH1R-mCherry was
noted (Fig. 7F–I). This co-localization was also increased by PTH(1–34)
(Fig. 7G, I), implicating a possible interaction between PPP1R14C with
PTH1R-mCherry. We thus carried out co-immunoprecipitation analysis
to test this view. PTH1Rwas indeed detected in the immune-complex of
PPP1R14C, so as VPS35 (Fig. 8A–C). The interaction was increased by
PTH(1–34) stimulation (Fig. 8A–C). These results thus suggest that
PTH(1–34) induced PTH1R interaction with VPS35, as well as PPP1R14C.ermittent and continued treatments of PTH(1–34). Primary cultured BMSCs from Vps35+/+
with PTH(1–34) intermittently (iPTH) (100 nM, 1-h per day, for 6 days) or continually
isolated after treatments and subjected to real time PCR analysis. (B–C) Real-time PCR
zed to β-actin. Ratio of RANKL/OPG was shown in C. The values of mean ± SD from 3-
y a post-hoc text, *, p b 0.05, ***, p b 0.001, signiﬁcant difference. (D–E) TRAP staining
Vps35+/+ and Vps35+/− mice. The coverslips containing WT BMMs were seeded onto
culture dishes. Cells were cultured in α-MEM medium supplemented with 10% FBS, 1%
s). Then, cells were treated with PBS (sham Control), PTH(1–34) intermittently (iPTH)
10 days and prepared for TRAP staining. Representative images are shown in D, the
e values of mean ± SD from 3-different experiments were presented. Data is determined
Fig. 5. Increased PTH(1–34)-induced anabolic response, but impaired catabolic response, in Vps35Ocn-Cre mice. P50 old Vps35f/f and Vps35Ocn-Cre male mice were administered once daily
injection of hPTH(1–34) (50 μg/Kg), or vehicle (0.9% sodium chloride), 5 days per week for 5 weeks. The femurs and sera samples collected after treatments were subjected to μCT and
ELISA/RIA assays, respectively. (A–E) The μCT analysis of femurs from Vps35f/f and Vps35Ocn-Cre littermates (at age of P85) treated with vehicle or PTH(1–34). Five different male mice of
each genotype per group were examined blindly. Representative 3D images were shown in A. Quantiﬁcation analyses (mean ± SD, n= 5) were presented in B-D. Two-way ANOVA *,
P b 0.05, **, P b 0.01, signiﬁcant difference. (F–H) ELISA/RIA analysis of serum osteocalcin (F), PYD (G), and serum calcium (H) levels of Vps35f/f and Vps35Ocn-Cre littermates (at age of
P85) treated with vehicle or PTH(1–34). Mean ± SD from 5 different animals per genotype. *, P b 0.05, signiﬁcant difference.
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PTH1R-PPP1R14C interaction was mediated or regulated by VPS35. To
address this issue, we ﬁrst asked if PTH1R interaction with PPP1R14C
is a direct binding event. Again, the recombinant GST-PPP1R14C fusion
protein was used for the in vitro GST pull down assay. As shown in Fig.
8D, PTH1R was present in the precipitates pulled down by GST-
PPP1R14C, but not GST. This result supports the notion for a direct inter-
action between PTH1R and PPP1R14C, which is likely independent on
VPS35. We second tested this view by carrying out PTH1R-PPP1R14C
co-immunoprecipitation assays in Vps35-KD cells. Interestingly, sup-
pressing VPS35's expression resulted in an even more PTH1R protein
in PPP1R14C immune-complex upon PTH(1–34) stimulation, compared
with that of VPS35-expressing cells (Fig. 8A–C), suggesting a negative
regulation of PTH1R-PPP1R14C interaction by VPS35. Third, we tested
this view by co-immunostaining analysis. The co-localization of PTH1R
with PPP1R14C was induced in both control and VPS35-deﬁcient
MC3T3 cells by PTH(1–34) in a time-dependent manner (Fig. 8E–F). In
control cells, their co-localization was peaked in 30 min, reduced in
45 min and after, of PTH(1–34) stimulation (Fig. 8E–F), corroborating
well with that of PTH(1–34) signaling events. In Vps35-KD cells, more in-
crease in PTH1R-PPP1R14C co-location was detected at 15- and 30-min
of PTH(1–34) stimulation, compared with that of controls (Fig. 8E–F).
Taken together, these results suggest that the two protein complexes,
PTH1R-PPP1R14C and VPS35-PPP1R14C, in MC3T3 cells, are both in-
creased by PTH(1–34) stimulation, but both complexes may suppress
each other, implicating PPP1R14C in PTH signaling.3.7. PPP1R14C's Contribution to the Enhanced PTH(1–34)-driven Endosomal
Signaling and Impaired Catabolic Response in Vps35-Deﬁcient OB-lineage
Cells
We then investigated PPP1R14C's role in regulating PTH(1–34) signal-
ing and function. To this end, we generated shRNA-PPP1R14C plasmid
and lentivirus,which efﬁciently suppressed exogenous and endogenous
PPP1R14C expression (Fig. S6). MC3T3 cells were infected with lentivi-
ruses encoding scramble shRNA (control), shRNA-PPP1R14C, shRNA-
Vps35 (Vps35-KD), and shRNA-Vps35 plus shRNA-PPP1R14C (Vps35-
KD + shR-PPP1R14C). In Vps35-KD MC3T3 cells, suppressing
PPP1R14C by its shRNA abolished VPS35-deﬁciency enhanced and
sustained PTH(1–34)-driven pCREB, pErk1/2, and pAkt (Fig. 9A–B). In
the presence of endogenous VPS35, suppression of PPP1R14C expres-
sion also reduced PTH(1–34)-driven phosphorylations of CREB and
Erk1/2 (Fig. S7). The increased PTH(1–34)-driven pCREB in Vps35-KD
cells was also attenuated by suppression of PPP1R14C by immunostain-
ing analysis (Fig. 9C–D). These results suggest that PPP1R14C is not only
required for efﬁcient PTH signaling in WT cells, but also necessary for
Vps35-deﬁciency-enhanced PTH(1–34) signaling, supporting the view
for PPP1R14C as a positive regulator of PTH signaling. The latter view
was further supported by the observations that expression of exoge-
nous PPP1R14C enhanced PTH(1–34)-driven pCREB signal in both control
and Vps35-KD MC3T3 cells (Fig. S8).
We further asked if PPP1R14C is required for Vps35-deﬁciency en-
hanced PTH(1–34) induction of cAMP, a canonical pathway. To our
Fig. 6. Increased PTH(1–34)-induced signaling and anabolic response, but reduced catabolic response, in BMSCs from Vps35Ocn-Cre mice. (A–C) Increased and sustained PTH(1–34)-induced
cAMP (A) and pCREB and pErk1/2 (B–C) in BMSCs from Vps35Ocn-Cre mice, compared with control BMSCs (from Vps35f/f mice). Cells were serum starved overnight and stimulated with
PTH(1–34)(100 nM) for the indicated time. For cAMP assay (in A), cells were lysedwith 0.1M HCl and centrifuged, the supernatant were assayed by using a cAMP ELISA kit. For evaluating
protein phosphorylation assays (in B–C), cell lysates were subjected to Western blot analyses using indicated antibodies. Quantiﬁcation analyses (in C) were carried out by ImageJ
software) of the data in (B). The values of mean ± SD from 3 separate experiments were shown. *, p b 0.05. (D–G) Real-time PCR analysis of the mRNA levels of osteocalcin, RANKL,
and OPG in BMSCs from control (Vps35f/f) and Vps35Ocn-Cre mice. The values are normalized to β-actin. Ratio of RANKL/OPG was shown in G. The values of mean ± SD from 3-
different experiments were presented. *, P b 0.05. (H–I) TRAP staining analyses of multiple nuclei cells (OCs) derived from co-cultures of BMMs plus osteoblasts (Vps35f/f vs Vps35Ocn-
Cre) in the presence of the indicated stimulations. Representative images were shown in (H), and quantiﬁcation data (mean ± SD, n= 3 separate experiments) were presented in (I).
*, P b 0.05.
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pression of PPP1R14C in Vps35-KD cells, compared to Vps35-KD cells
(Fig. 9E). In aggregate, these results support a working model, in
whichVPS35deregulates both cell surface and endosomal PTH(1–34) sig-
naling, but PPP1R14C appears to promote endosomal, but not cell sur-
face cAMP, signaling (Fig. 9F).
We then addressed whether PPP1R14C is involved in the impaired
PTH(1–34)-driven catabolic response in Vps35-deﬁcient cells. First, the
control, Vps35-KD plus scramble shR, and Vps35-KD plus shR-
PPP1R14C MC3T3 cells were treated with PTH(1–34) in two settings,
iPTH and cPTH, as illustrated in Fig. 4A. As shown in Fig. 10A–10B, the
iPTH treatment led to a signiﬁcant increase in expressions of RANKL
and OPG in control, Vps35-KD plus scramble shR, and Vps35-KD plus
shR-PPP1R14C MC3T3 cells. The ratio of RANKL/OPG was not signiﬁ-
cantly altered among the three groups- control, Vps35-KD plus scram-
ble shR, and Vps35-KD plus PPP1R14C-KD (Fig. 10C), supporting the
view for a normal anabolic-like response in these cells. However, it is
of interest to note that whereas Vps35-KD plus scramble shR MC3T3
cells showed an impairment in catabolic response induced by cPTH
treatment (viewed by the ratio of RANKL/OPG)(Fig. 10C), such a cata-
bolic response was nearly normal in cells of Vps35-KD plus shR-
PPP1R14C (Fig. 10C). These results suggest an amelioration of the im-
paired catabolic response by suppressing PPP1R14C expression inVps35-deﬁcient MC3T3 cells. We second tested this view by examining
osteocalcin, RANKL and OPG's expression in these 3-groups of cells in
response to PTH(1–34) stimulations for a short time course (1, 2, 4, 6 to
12 h). Note that PTH(1–34)-induced RANKL's transcripts were compara-
ble among the three-groups of MC3T3 cells (control, Vps35-KD plus
scramble shR, and Vps35-KD plus shR-PPPP1R14C)(Fig. 10D). In con-
trast, OPG's transcripts were differentially regulated in the three-groups
of cells by PTH(1–34): decreased in control cells, increased in Vps35-KD
plus scramble shR cells, and without an change in Vps35-KD cells plus
shR-PPP1R14C cells (Fig. 10E). Thus, suppression of PPP1R14C in
Vps35-KD cells resulted in a partial restore of the catabolic response
(e.g., ratio of RANKL/OPG) (Fig. 10F). In aggregate, these results demon-
strate the necessity of PPP1R14C not only for the enhancement of the
endosomal/non-canonical PTH(1–34) signaling, but also for the impair-
ment in PTH(1–34)-driven catabolic response due to Vps35-deﬁciency
(Fig. 10G).
4. Discussion
There is increasing emphasis towards our understanding how
PTH1R signaling is regulated, thus mediating PTH's dual functions: ana-
bolic and catabolic responses. Here we provide several lines of evidence
for VPS35, a major component of retromer, in regulating PTH1R
Fig. 7. VPS35 interaction with PPP1R14C. (A) Predicted proteins that may interact with VPS35 by Emililab. (B–C) Co-localization of endogenous PPP1R14C, but not PPP1R14A, with
exogenous GFP-VPS35 in MC3T3 cells. Representative images were shown in (B). Quantiﬁcation analyses of the optical intensity of GFP-Vps35 co-localization with PPP1R14A or
PPP1R14C over total GFP-VPS35 were presented in C. Bar, 10 μm. (D–E) Co-immunoprecipitation of PPP1R14C with VPS35. HEK293T cells were transfected with V5-tagged PPP1R14C
and FLAG-tagged VPS35. 48 h post transfection, cell extracts (~500 μg) were immunoprecipitated with V5(PPP1R14C), and the resulting immunoprecipitates were subjected to
immunoblot by using anti-Flag (for VPS35) antibody. IgG antibody was used as a negative control for immunoprecipitation, and 50 μg of the cell lysates was used as input. The data
presented is a representative blot of 3 independent experiments. Quantiﬁcation analyses were shown in E. (F–I) GFP-VPS35-PPP1R14C co-localization was decreased in MC3T3 cells
expressing PTH1R-mCherry, but increased by PTH(1–34) stimulation. MC3T3 cells expressing PTH1R-mCherry and GFP-VPS35 were stimulated with control or PTH(1–34)(100 nM) for
30 min. Cells were ﬁxed and subjected to the immunostaining analysis with indicated antibodies. Representative images were shown, and the images marked with white squares
were ampliﬁed and shown in right corners. The quantiﬁcation analyses of the optical intensity for the co-localization (GFP-VPS35 with endogenous PPP1R14C) over total GFP-VPS35
or the co-localization of PTH1R-PPP1R14C over total PTH1R were presented in H and I, respectively. Bar, 10 μm. The values of mean ± SD (n= 30 cells from 3-different experiments)
were presented. *, P b 0.05. (J) In vitro GST pull down assay using indicated GST fusion proteins was carried out in HEK293 lysates expressing Flag-Vps35. The precipitates associated
with the GST beads were subjected to the Western blot analysis using indicated antibodies.
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vivo. First, VPS35 promotes PTH(1–34)-induced PTH1R translocation to
the Golgi apparatus, which appears to be critical not only for retrieval
of PTH1R from lysosomes to prevent its degradation, but also for termi-
nation of PTH1R signaling. Second, VPS35 in OBs is required for main-
taining bone mass as well as PTH(1–34)-induced catabolic response.
Third, PPP1R14C, an inhibitory subunit of PP1 phosphatase, interacts
with not only VPS35, but also PTH1R; and it is involved in the activation
of the non-canonical PTH1R signaling pathway and PTH(1–34)-induced
catabolic response. Finally, our results support the view that PTH signal-
ing events are closely coupled in time and spatial-dependent manners,
which may be critical for PTH(1–34)-driven anabolic and catabolic
responses.
The results that VPS35 interacts with PTH1R, and VPS35 is necessary
for PTH(1–34)-induced PTH1R's endosome-to-Golgi translocation (Fig.
2), support the view for PTH1R as a cargo of VPS35/retromer not only
in HEK293 cells (Feinstein et al., 2011), but also in OB-lineage cells. In-
terestingly, both PTH1R-VPS35 interaction and VPS35-mediated
PTH1R's endosome-to-Golgi translocation were increased by PTH(1–34)
stimulation (Fig. 2). Such endosome-to-Golgi translocation of PTH1R is
time-dependent, which appears to be crucial for preventing PTH1R deg-
radation as well as turning off PTH1R signaling. The latter view is in
agreement with recent reports that retromer terminates not only PTH-,but also vasopressin-induced increase of cAMP in HEK 293 cells
(Feinstein et al., 2011; Feinstein et al., 2013). In addition to suppress
these GPCR signaling, VPS35/retromer also inhibits RANK signaling in
macrophages likely by promoting RANK endosome to Golgi translocation
(Xia et al., 2013b). In aggregate, VPS35/retromer regulates GPCR-family
receptors' trafﬁcking, and VPS35/retromer-mediated endosome-to-
Golgi trafﬁcking may be critical not only for retrieval of the receptors/
cargos, but also for suppression of their signaling.
Note that whereas PTH1R signaling is enhanced and prolonged in
Vps35-deﬁcient cells, PTH1R's degradation was accelerated. These re-
sults seem discrepant, but they are likely to be linked. Note that the
time course for signaling studies (within 1-h) is shorter than those for
protein degradation assays (1 to 8 h). It is possible that when the recep-
tor (PTH1R) signaling is constitutively activated due to Vps35/
retromer-deﬁciency, PTH1R's degradation machinery is thus turning
on to prevent further activation of its down-stream signaling events.
This view is in agreement with the notion for two cellular mechanisms
to terminate a receptor signaling: one (a reversible/physiological one) is
positively regulated by VPS35/retromer, and the other one (receptor
degradation, an irreversible mechanism) is negatively regulated by
VPS35/retromer.
HowdoesVPS35/retromer turn off PTH1R signaling?Herewepropose
a working model that is depicted in Fig. 10F. In this model, VPS35/
Fig. 8. PTH1R interaction with PPP1R14C. (A-C) Co-immunoprecipitation of PTH1R- PPP1R14C complex in the presence or absence of VPS35. HEK293T cells were transfected with
indicated plasmids. 48 h post transfection, cells were treated with or without PTH(1–34)(100 nM) for 30 min. Cell lysates were immunoprecipitated with anti-V5 (for PPP1R14C) or
anti-mCherry (for PTH1R) antibodies, respectively. The resulting precipitates were subjected to immunoblotting analysis using indicated antibodies. The data presented are
representative blots of 3-independent experiments. Quantiﬁcation analyses were shown in C. (D) In vitro GST pull down assay using indicated GST fusion proteins was carried out in
HEK293 lysates expressing PTH1R-mCherry. The precipitates associated with the GST beads were subjected to the Western blot analysis using indicated antibodies. (E–F) Co-
localization of PTH1R with PPP1R14C in MC3T3 cells in the presence or absence of VPS35. MC3T3 cells were co-transfected with indicated plasmids. 48 h post transfection, cells were
stimulated with PTH(1–34)(100 nM) for the indicated time, and then subjected to the immunostaining analysis with indicated antibodies. Representative images were shown, and
images marked with white squares were ampliﬁed and shown in right top corners. Quantiﬁcation analyses of the optical intensity for the co-localization of PTH1R-PPP1R14C over total
PTH1R were presented in E. Bar, 10 μm. The values of mean ± SD (n= 25 cells from 3-different experiments) were shown. *, P b 0.05, signiﬁcant difference.
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PTH1R-PPP1R14C complex, thus, allowing PP1 phosphatase to dephos-
phorylate the downstream signaling proteins, in particular, the
endosomal signaling pathway, such as pCREB, pErk1/2, and pAkt (Fig.
9F). This model is in line with the following observations. PPP1R14C, an
inhibitory subunit of PP1, forms complex with both VPS35/retromer
(Fig. 7) and PTH1R (Fig. 8). Although both complex (VPS35-PPP1R14C
and PTH1R-PPP1R14C) were stimulated by PTH(1–34) (Figs. 7-8), PTH1R-
PPP1R14C complex appears to be negatively regulated by VPS35 (Fig.
8), implicating that both VPS35/retromer and PTH1R may compete for
the interactionwith PPP1R14C. PPP1R14C appears to selectively promote
PTH1R-mediated endosomal, but not cell surface, signaling. By interacting
with PPP1R14C, VPS35/retromer may terminate PTH's endosomal signal-
ing by reducing PPP1R14C binding with PTH1R, releasing PPP1R14C's in-
hibitory effect on PP1 phosphatase, and thus enhancing PP1-driven
dephosphorylations of endosomal signaling proteins (e.g., pErk1/2,
pAkt, and pCREB)(Fig. 9F). When VPS35 is depleted, PPP1R14C may be
largely in association with PTH1R complex in endosomes, where it
could suppress PP1-mediated de-phosphorylations, and thus enhancing/
sustaining PTH(1–34)-driven endosomal/non-canonical phosphorylation
events (Fig. 9F). It is of interest to note that PPP4C, a catalytic subunit of
phosphatase, is also found to be involved in endosome-to-Golgi retrieval
of membrane proteins (Borroni et al., 2014).
What is the functional signiﬁcance of VPS35/retromer-turning off
PTH1R signaling? The increased and sustained PTH(1–34) signaling in
Vps35-deﬁcient OB-lineage cells corroborates well with the impaired
PTH(1–34)-driven catabolic response (e.g., RANKL/OPG-expression and
OC genesis). Suppression of PPP1R14C expression diminished not only
the sustained endosomal PTH(1–34) signaling, but also the impaired cat-
abolic response due to VPS35-deﬁciency (Figs. 9-10). Theseobservations lead to the speculation that VPS35/retromer turning off
the endosomal PTH(1–34) signalingmay be critical for PTH(1–34)-induced
catabolic response and bone remodeling, thus preventing a large bone-
gain response. It is noteworthy that our results for PTH(1–34) responses
in Vps35-deﬁcient cells/mice are remarkably similar to that described
for β-arrestin-biased ligand (D-Trp12,Tyr34)-PTH(7–34)'s effect, which
stimulates PTH1R-mediated endosomal/non-canonical β-arrestin sig-
naling, promotes anabolic bone formation, but suppresses catabolic
bone resorption (Gesty-Palmer et al., 2009; Whalen et al., 2011). It is
also of interest to note that β-arrestins prolong rather than attenuate
cAMP signaling triggered by GPCRs, including PTH1R and vasopressin
receptor (van der Lee et al., 2013; Vilardaga et al., 2012; Whalen et al.,
2011). Such β-arrestin mediated signaling is believed to be a non-ca-
nonical or endosomal signaling, as it is different from that of canonical
or cell surface model. In the cell surface model, β-arrestin is thought
to desensitize GPCR signaling at the plasma membrane by physically
interacting with activated GPCR, such as rhodopsin and the β2-AR
(Whalen et al., 2011). Another intriguing observation is that the struc-
tures of β-arrestins and the Vps26 subunit of retromer have a striking
resemblance (Collins et al., 2008). Although the functional signiﬁcance
of this similarity remains unknown, it is possible that via VPS26,
VPS35/retromer may complete with β-arrestin2 in binding to PTH1R
in endosomes, thus, suppresses β-arrestin mediated non-canonical sig-
naling. While this alternative hypothesis is of interest, it requires addi-
tional investigations.
In summary, the data presented in this manuscript demonstrate a
critical function of VPS35 in regulating PTH1R trafﬁcking. This event
andVPS35-interactionwith PPP1R14C appear to be essential for turning
off PTH1R's endosomal signaling, and promoting PTH1R-mediated cata-
bolic response and bone remodeling.
Fig. 9. Requirement of PPP1R14C for the enhanced PTH(1–34)-driven endosomal signaling in Vps35-KD MC3T3 cells. (A-B) Western blot analysis of PTH(1–34)-driven signaling in Control,
Vps35-KD and Vps35-KD plus PPP1R14C-KD MC3T3 cells. Representative blots from 3-independent experiments were shown in A. The data were quantiﬁed by ImageJ software and
presented in B as mean ± SD. *, P b 0.05. (C–D) Immunostaining analysis of pCREB in Vps35-KD and Vps35-KD plus PPP1R14C-KD MC3T3 cells treated with or without PTH(1–34) for
15 min. Representative images were shown in C. The pCREB levels in transfected cells (marked by BFP/GFP with dashed lines) were normalized to un-transfected cells in the same
ﬁeld of view. The quantiﬁcation analyses shown in (D) were mean ± SD (n = 30 cells from 3-different assays). *, P b 0.05. Bar, 10 μm. (E) ELISA analysis of cAMP production in
Control, Vps35-KD and Vps35-KD plus PPP1R14C-KD MC3T3 cells. Cells were serum starved overnight and stimulated with PTH(1–34)(100 nM) for the indicated time in E. Then, cells
were lysed with 0.1 M HCl and centrifuged, the supernatant were assayed by using a cAMP ELISA kit. (F) Illustration of a working model for a possible role of VPS35-PPP1R14C
interaction in regulating PTH signaling.
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